Mirikizumab

Mirikizumab (INN;[1] trade name Omvoh; development code LY3074828) is a human monoclonal antibody designed for the treatment of immune-mediated diseases psoriasis and ulcerative colitis.

Mirikizumab
Monoclonal antibody
Type	?
Source	Humanized (from mouse)
Target	interleukin 23A
Clinical data
Trade names	Omvoh
Other names	LY3074828
ATC code	None
Legal status
Legal status	Rx in Japan
Identifiers
CAS Number	1884201-71-1
ChemSpider	none
UNII	Z7HVY03PHP
KEGG	D11123
Chemical and physical data
Formula	C₆₃₈₀H₉₈₄₂N₁₆₈₆O₂₀₀₄S₄₈
Molar mass	143767.59 g·mol⁻¹

This drug was developed by Eli Lilly and Co.[2] In 2023, mirikizumab was approved as a first-in-class treatment for adults with moderately to severely active ulcerative colitis in Japan;[3] however, approval in the United States has not been granted due to manufacturing issues.[4]

References

World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
Statement On A Nonproprietary Name Adopted By The USAN Council - Mirikizumab, American Medical Association.
"U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab" (Press release). Eli Lilly and Company. April 13, 2023.
"FDA rejects Eli Lilly's ulcerative colitis prospect mirikizumab, citing manufacturing shortfalls". Fierce Pharma. April 14, 2023.

Monoclonal antibodies for the immune system

Immune system

Human	Immunosuppression: Abrilumab Adalimumab^# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive: Apolizumab^§ Aselizumab Atezolizumab Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab^‡ Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Inebilizumab Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab^† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Immune activation: Dostarlimab Other: Ibalizumab
Chimeric + humanized	Otelixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatory lesions

Mouse	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.